

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement

Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 04, 2019
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 12, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 10, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 25, 2015
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2013
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2012
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Valerio Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 17, 2011
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Valerio Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
